P03-242 - Efficacy and tolerability of quetiapine XR 400/600/800mg/day in acute schizophrenia: a post-hoc analysis of data from two pooled randomised studies

R. Kahn,A. Kalali,U. Gustafsson,S. Nyberg
DOI: https://doi.org/10.1016/s0924-9338(11)73116-9
2011-01-01
European Psychiatry
Abstract:Introduction Data from two, identically designed, placebo-controlled, randomised, double-blind clinical trials (D1444C00132+D1444C00133) for once-daily extended-release quetiapine fumarate (QTP-XR) were pooled and analysed. Objective Evaluate dose response, efficacy and safety for QTP-XR in schizophrenia. Methods Post-hoc analysis of data from patients receiving QTP-XR 400, 600, 800 mg/day or placebo. Endpoints: least squares means (LSM) change from baseline to Day 42 in PANSS total and positive and negative subscale scores. No corrections for multiplicity were performed. Adverse events (AEs) were recorded. Results 914 patients were included; PANSS scores were assessed in the MITT population (n = 889). LSM change from baseline in PANSS total score diverged significantly from placebo at: Day 14 for QTP-XR 800 mg/day (-15.3 vs -12.1 for placebo; p = 0.018); Day 21 for 600 mg/day (-17.3 vs -14.2; p = 0.039); Day 42 for 400 mg/day (-19.2 vs -15.4; p = 0.033). Jonckheere-Terpstra analysis of change in PANSS total score at Day 42 showed a significant QTP-XR dose response (p = 0.0196; p  Conclusions QTP-XR was generally well tolerated and demonstrated efficacy that increased with dose in schizophrenia. Financial support: AstraZeneca.
What problem does this paper attempt to address?